Скачать или смотреть 2025 WMIF | Cardiovascular Disease | Emerging Treatments

Ischemic heart disease remains the leading cause of death globally and attracts significant investment by pharma and biotech. This panel will explore the evolving pharmaceutical pipeline for cardiovascular disease, focusing on promising advances such as Lipoprotein(a) reduction, oral PCS-K9s, Factor XI inhibitors, the role of GLP-1s in cardiovascular health, CETP inhibitors, and aldosterone synthase inhibitors (ASIs). The session will examine how these breakthroughs may shift clinical practice and improve long-term outcomes for patients living with CVD.

Moderators
Tazeen Ahmad, SMid-Cap Biotech Analyst, BofA Securities
Tim Anderson, MD, Pharmaceutical Analyst, BofA Securities

Speakers
Brian Bergmark, MD, Interventional Cardiologist, Brigham and Women’s Hospital; Assistant Professor of Medicine, Harvard Medical School
Erin Bohula, MD, DPhil, Cardiologist, TIMI Study Group, Brigham and Women’s Hospital; Assistant Professor of Medicine, Harvard Medical School
Calum MacRae, MD, PhD, Vice Chair for Scientific Innovation, Department of Medicine, Brigham and Women's Hospital; Professor of Medicine, Harvard Medical School
Pradeep Natarajan, MD, Director of Preventive Cardiology, Paul & Phyllis Fireman Endowed Chair in Vascular Medicine, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School